Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma

被引：5

作者：

Zhang, Jie Qing ^{[1
]}

Zhao, Bing Bing ^{[1
]}

Wang, Mao Mao ^{[1
]}

Li, Li ^{[1
]}

机构：

[1] Guangxi Med Univ, Dept Gynecol Oncol, Canc Hosp, Nanning, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

关键词：

niraparib; ovarian carcinosarcoma; maintenance therapy; case report; gynecologic oncology; DOUBLE-BLIND; OPEN-LABEL; CARCINOMA; OLAPARIB; CANCER; PHASE-2; MULTICENTER; RUCAPARIB;

D O I：

10.3389/fonc.2021.603591

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian carcinosarcoma (OCS) is a rare, highly aggressive and rapidly progressing malignant tumor with an extremely poor prognosis. So far, due to the low incidence of OCS, there are no large-scale prospective studies exploring the standard care of OCS patients. There is no uniform and effective treatment for OCS. Within the development of precision medicine, targeted therapies (such as PARP inhibitors) have been widely used in epithelial ovarian cancer and various other solid tumors. Here, we report a BRCAwt patient with advanced OCS who experienced a second and a third cytoreductive surgery in June 2017 and October 2019 and has been on niraparib maintenance therapy for more than 20 months after receiving second-line and third-line chemotherapy.

引用

页数：6

共 14 条

[1] Significant Tumor Response to the Poly (ADP-ribose) Polymerase Inhibitor Olaparib in Heavily Pretreated Patient With Ovarian Carcinosarcoma Harboring a Germline RAD51D Mutation [J].

Chandran, Elias A. ;

Kennedy, Ian .

JCO PRECISION ONCOLOGY, 2018, 2 :1-4

[2] Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Coleman, Robert L. ;

Oza, Amit M. ;

Lorusso, Domenico ;

Aghajanian, Carol ;

Oaknin, Ana ;

Dean, Andrew ;

Colombo, Nicoletta ;

Weberpals, Johanne, I ;

Clamp, Andrew ;

Scambia, Giovanni ;

Leary, Alexandra ;

Holloway, Robert W. ;

Amenedo Gancedo, Margarita ;

Fong, Peter C. ;

Goh, Jeffrey C. ;

O'Malley, David M. ;

Armstrong, Deborah K. ;

Garcia-Donas, Jesus ;

Swisher, Elizabeth M. ;

Floquet, Anne ;

Konecny, Gottfried E. ;

McNeish, lain A. ;

Scott, Clare L. ;

Cameron, Terri ;

Maloney, Lara ;

Isaacson, Jeff ;

Goble, Sandra ;

Grace, Caroline ;

Harding, Thomas C. ;

Raponi, Mitch ;

Sun, James ;

Lin, Kevin K. ;

Giordano, Heidi ;

Ledermann, Jonathan A. .

LANCET, 2017, 390 (10106) :1949-1961

[3] Serous ovarian carcinoma recurring as a heterologous carcinosarcoma [J].

Ferrandina, Gabriella ;

Carbone, Arnaldo ;

Zannoni, Gian Franco ;

Martinelli, Enrica ;

Testa, Antonia Carla ;

Gallotta, Valerio ;

De Ninno, Maria ;

Scambia, Giovanni .

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2007, 33 (01) :95-99

[4] Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study [J].

Gelmon, Karen A. ;

Tischkowitz, Marc ;

Mackay, Helen ;

Swenerton, Kenneth ;

Robidoux, Andre ;

Tonkin, Katia ;

Hirte, Hal ;

Huntsman, David ;

Clemons, Mark ;

Gilks, Blake ;

Yerushalmi, Rinat ;

Macpherson, Euan ;

Carmichael, James ;

Oza, Amit .

LANCET ONCOLOGY, 2011, 12 (09) :852-861

[5] Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes [J].

Hodgson, D. R. ;

Dougherty, B. ;

Lai, Z. ;

Grinsted, L. ;

Spencer, S. ;

O'Connor, M. J. ;

Ho, T. W. ;

Robertson, J. D. ;

Lanchbury, J. ;

Timms, K. ;

Gutin, A. ;

Orr, M. ;

Jones, H. ;

Gilks, B. ;

Womack, C. ;

Sun, J. ;

Yelensky, R. ;

Gourley, C. ;

Ledermann, J. ;

Barrett, J. C. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 :S90-S90

[6] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial [J].

Ledermann, Jonathan ;

Harter, Philipp ;

Gourley, Charlie ;

Friedlander, Michael ;

Vergote, Ignace ;

Rustin, Gordon ;

Scott, Clare L. ;

Meier, Werner ;

Shapira-Frommer, Ronnie ;

Safra, Tamar ;

Matei, Daniela ;

Fielding, Anitra ;

Spencer, Stuart ;

Dougherty, Brian ;

Orr, Maria ;

Hodgson, Darren ;

Barrett, J. Carl ;

Matulonis, Ursula .

LANCET ONCOLOGY, 2014, 15 (08) :852-861

[7] Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer [J].

Ledermann, Jonathan ;

Harter, Philipp ;

Gourley, Charlie ;

Friedlander, Michael ;

Vergote, Ignace ;

Rustin, Gordon ;

Scott, Clare ;

Meier, Werner ;

Shapira-Frommer, Ronnie ;

Safra, Tamar ;

Matei, Daniela ;

Macpherson, Euan ;

Watkins, Claire ;

Carmichael, James ;

Matulonis, Ursula .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (15) :1382-1392

[8] Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer [J].

Mirza, M. R. ;

Monk, B. J. ;

Herrstedt, J. ;

Oza, A. M. ;

Mahner, S. ;

Redondo, A. ;

Fabbro, M. ;

Ledermann, J. A. ;

Lorusso, D. ;

Vergote, I. ;

Ben-Baruch, N. E. ;

Marth, C. ;

Madry, R. ;

Christensen, R. D. ;

Berek, J. S. ;

Dorum, A. ;

Tinker, A. V. ;

du Bois, A. ;

Gonzalez-Martin, A. ;

Follana, P. ;

Benigno, B. ;

Rosenberg, P. ;

Gilbert, L. ;

Rimel, B. J. ;

Buscema, J. ;

Balser, J. P. ;

Agarwal, S. ;

Matulonis, U. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22) :2154-2164

[9] Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial [J].

Moore, Kathleen N. ;

Secord, Angeles Alvarez ;

Geller, Melissa A. ;

Miller, David Scott ;

Cloven, Noelle ;

Fleming, Gini F. ;

Hendrickson, Andrea E. Wahner ;

Azodi, Masoud ;

DiSilvestro, Paul ;

Oza, Amit M. ;

Cristea, Mihaela ;

Berek, Jonathan S. ;

Chan, John K. ;

Rimel, Bobbie J. ;

Matei, Daniela E. ;

Li, Yong ;

Sun, Kaiming ;

Luptakova, Katarina ;

Matulonis, Ursula A. ;

Monk, Bradley J. .

LANCET ONCOLOGY, 2019, 20 (05) :636-648

[10]

National Comprehensive Cancer Care Network, 2021, OV CANC NCCN GUID VE

← 1 2 →